PZ0039

Lorlatinib

≥98% (HPLC)

• Synonym(s): (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H.8,4-(metheno)pyrazolo[4,3.h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile, PF-06463922, PF-6463922
• Empirical Formula (Hill Notation): C₂₁H₁₉FN₆O₂
• CAS Number: 1924207-18-0
• Molecular Weight: 406.41
• MDL number: MFCD28144520
• UNSPSC Code: 51111800
• NACRES: NA.77

Properties

• Assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D -95 to -115°, c = 0.5 in methanol
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: room temp
• SMILES string: NC1=C(O[C@@H](C2=C3C=CC(F)=C2)C)C=C(C4=C(C#N)N(C)N=C4CN(C)C3=O)C=N1
• InChI key: IIXWYSCJSQVBQM-LLVKDONJSA-N

Description

Biochem/physiol Actions

Lorlatinib (PF-06463922) is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against most known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. It is in clinical trials for the treatment of non–small cell lung cancer (NSCLC).

Potent, selective inhibitor of both ALK and ROS1

Legal Information

Sold for research purposes under agreement from Pfizer Inc.

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable